XXXX - glycaemic status and mortality.

@entity1 @entity6 @entity5710 @entity1028 @entity413
AIMS: The prevalence of @entity6 ( @entity6 ) and mortality with respect to glycaemic status in @entity1 with @entity1028 ( @entity1028 ) was evaluated. Glycaemic status was assessed by an oral @entity413 tolerance test (OGTT) and by HbA1c. METHODS: Sixty-six @entity1 with @entity1028 admitted to the vascular surgery unit for elective surgery between October 2006 and September 2007 were included. Seven @entity1 had previously known @entity6 . OGTT and HbA1c results were available from 58 @entity1 . The @entity1 were categorized as having @entity6 , @entity5710 and normoglycaemia according to the WHO's and American @entity6 Association's criteria. RESULTS: The prevalence of newly diagnosed @entity6 according to the OGTT and HbA1c results were 12% and 14% respectively. Mean follow-up time was 68months and all-cause mortality 43%. HbA1c was an independent predictor for mortality in the @entity6 category. Hazard ratio of all-cause mortality in the @entity6 category defined by the HbA1c values was 6.35, 95% [CI 1.49-27.1]; p = 0.01. CONCLUSIONS: @entity6 defined by HbA1c>= 6.5% is an important determinant of mortality following surgical treatment for @entity1028 . Half the @entity1 with @entity1028 and @entity6 were unaware of their @entity6 diagnosis. All @entity1 with @entity1028 should be tested for @entity6 using HbA1c. The results should be confirmed in a larger prospective study.
